Zeta IMP-3 Antibody. Zeta’s recombinant rabbit antibody recognizes IMP-3 (Insulin-like growth factor II mRNA binding protein 3), an oncofetal RNA-binding protein that regulates targets such as insulin-like growth factor-2 and beta-actin. IMP-3 plays a major role in early embryogenesis involving the development of the intestine, thymus, pancreas, and kidneys. IMP-3 mRNA transcript and protein have been demonstrated in high levels in pancreatic cancer tissues but not in benign lesions of the pancreas, chronic pancreatitis, or normal pancreatic tissues. IMP-3 can be used to distinguish between pancreatic ductal adenocarcinoma from chronic sclerosing pancreatitis. IMP-3 expression has also been found in a variety of other human cancers including renal cell carcinoma, adenocarcinoma of the uterine cervix, endometrial carcinoma, adenocarcinoma of the esophagus, malignant melanoma, Merkel cell carcinoma, urothelial carcinoma, neuroendocrine carcinoma of the lung, adenocarcinoma of the pancreas, and triple negative breast cancer.
Zeta Corporation is a leader in recombinant monoclonal IVD antibodies for immunohistochemistry (IHC) offering 400+ tumor and tissue specific relevant products developed by a pathologist for pathologists. Visit Precision Recombinant Antibodies – IVD Antibodies – About Zeta Corporation (zeta-corp.com) to learn more about Zeta Corporation.